ERBB2 and gastric cancer: A phase Ib/II, open-label, dose-escalation study is investigating the novel anti-HER2 mAb, margetuximab, in combination with pembrolizumab in patients with advanced HER2-amplified GC who are refractory to standard trastuzumab-based combination chemotherapy (NCT02689284) [88].